title: [Change in serum basic fibroblast growth factor level and its relationship to pulmonary arterial pressure in patients with acute exacerbation of chronic cor pulmonale on plateau].
abstract: OBJECTIVE
  To assess the role of serum basic fibroblast growth factor (bFGF) in the development of hypoxic pulmonary hypertension in the patients with chronic cor pulmonale on highland (HACCP).
  
  
  METHODS
  The levels of bFGF in serum of 38 patients with HACCP in the acute exacerbation stage, 30 patients with chronic obstructive pulmonary disease (COPD) in the remission stage and 30 normal control subjects were measured by sandwich enzyme-linked immunoadsorbent assay (ELISA). The mean pulmonary arterial pressure (MPAP) was measured by echocardiography. The partial pressure of oxygen in artery blood (PaO(2)) was measured by blood gas analyzer.
  
  
  RESULTS
  The level of serum bFGF [(87.54+/-12.15) ng/L] and MPAP [(45.86+/-5.63)mm Hg (1 mm Hg=0.133 kPa)] in the patients with HACCP were significantly higher than those in the patients with COPD [(55.72+/-9.08) ng/L, (22.95+/-2.56)mm Hg, respectively, both P<0.01], those of the patients with COPD were both significantly higher than those of the normal control subjects [(49.83+/-8.78)ng/L, (20.34+/-2.23)mm Hg, respectively, both P<0.05]. The PaO(2) [(38.79+/-4.56)mm Hg] in the patients with HACCP was significantly lower than those in patients with COPD and normal subjects [(58.22+/-6.18) mmHg and (66.57+/-5.48)mm Hg, respectively, all P<0.01]. The level of serum bFGF in the patients with HACCP and the patients with COPD was positively correlated with MPAP (cor pulmonale group r=0.788, P<0.01; COPD group r=0.674, P<0.01)],negatively correlated with PaO(2) (cor pulmonale group r=-0.735, P<0.01; COPD group r=-0.587, P<0.01)).
  
  
  CONCLUSIONS
  The level of serum bFGF in patients with HACCP is significantly increased; it may play an important role in the process of sustained hypoxic pulmonary hypertension in patients with HACCP.
authors.affiliation: Department of Respiratory Disease of Lanzhou Command, the Fourth Hospital of PLA, Xi'ning 810007, Qinghai, China.
authors.forename: Sheng-yue
authors.initials: SY
authors.lastname: Yang
authors.forename: Jun-li
authors.initials: JL
authors.lastname: Shen
authors.forename: En-zhi
authors.initials: EZ
authors.lastname: Feng
authors.forename: Jun
authors.initials: J
authors.lastname: Xu
authors.forename: Ning-xia
authors.initials: NX
authors.lastname: Huang
authors.forename: Li-hong
authors.initials: LH
authors.lastname: Zhao
authors.forename: Xue-mei
authors.initials: XM
authors.lastname: Wu
authors.forename: Dong-tian
authors.initials: DT
authors.lastname: Zhang
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000368:Aged; D000531:Altitude; D001794:Blood Pressure / Q000502:physiology; D016022:Case-Control Studies; D002908:Chronic Disease; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D011651:Pulmonary Artery / Q000503:physiopathology*; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000150:complications / Q000503:physiopathology; D011660:Pulmonary Heart Disease / Q000097:blood* / Q000150:complications / Q000503:physiopathology
chemical_list: D016222:Fibroblast Growth Factor 2